天臣医疗(688013) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2024 reached ¥69,352,341.74, an increase of 27.94% compared to the same period last year[2] - Net profit attributable to shareholders was ¥13,900,441.12, representing a significant increase of 113.12% year-over-year[2] - Net profit excluding non-recurring items for Q3 2024 was ¥12,696,728.29, up 166.34% from the previous year[2] - Basic earnings per share for Q3 2024 was ¥0.17, an increase of 112.50% compared to the same period last year[3] - Net profit for the first three quarters of 2024 was ¥42,751,708.14, representing a significant increase of 29.2% from ¥33,111,864.38 in the previous year[17] - Basic earnings per share for the first three quarters of 2024 were ¥0.53, compared to ¥0.41 in the same period of 2023, indicating a growth of 29.3%[18] - The net profit for Q3 2024 was CNY 44,687,057.66, an increase of 42.5% compared to CNY 31,313,861.85 in Q3 2023[26] - Operating profit for Q3 2024 reached CNY 48,821,246.38, up 45.2% from CNY 33,617,864.49 in the same period last year[26] Assets and Liabilities - Total assets as of the end of the reporting period were ¥671,922,540.80, reflecting a growth of 7.23% from the end of the previous year[3] - The total assets of the company increased to ¥671,922,540.80 from ¥626,608,586.15 in the previous year, indicating growth in the company's asset base[16] - The total assets of the company increased to CNY 688,500,150.29 as of September 30, 2024, compared to CNY 640,931,269.07 at the end of 2023[24] - The company's total liabilities as of the end of the third quarter of 2024 amounted to ¥100,001,593.89, compared to ¥55,084,046.36 at the end of the same period in 2023, showing a substantial increase[16] - The company's total liabilities amounted to CNY 97,447,228.11, an increase from CNY 52,202,358.12 in the previous year[24] Cash Flow - The company reported a net cash flow from operating activities of ¥38,520,695.40 year-to-date, down 21.69% compared to the previous year[2] - The net cash flow from operating activities was CNY 38,520,695.40, down 21.6% from CNY 49,187,863.86 in the previous year[20] - The net cash flow from operating activities for Q3 2024 was CNY 32,613,365.44, down 34.7% from CNY 49,976,227.27 in Q3 2023[29] - The company's cash and cash equivalents decreased to CNY 34,634,760.88 from CNY 211,533,558.01, representing a decline of approximately 83.7%[11] - The company reported a cash and cash equivalents balance of CNY 34,634,760.88 at the end of the period, down from CNY 175,054,567.39 at the end of the previous year[21] - The company’s cash flow from financing activities resulted in a net outflow of CNY -13,546,861.07, worsening from CNY -4,693,484.37 in the previous year[21] Research and Development - R&D expenses totaled ¥9,161,777.22 for Q3 2024, accounting for 13.21% of revenue, a decrease of 1.51 percentage points year-over-year[3] - Research and development expenses for the first three quarters of 2024 were ¥24,734,156.26, slightly up from ¥24,686,254.99 in 2023, reflecting a focus on innovation[16] - Research and development expenses for Q3 2024 were CNY 24,734,156.26, slightly up from CNY 24,686,254.99 in Q3 2023[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,282[7] - The top two shareholders, Chen Wangyu and Chen Wangdong, hold 25.85% and 25.79% of shares, respectively[7] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[10] Operating Costs and Revenue - Total operating revenue for the first three quarters of 2024 reached ¥202,085,550.04, an increase of 11.3% compared to ¥181,700,399.51 in the same period of 2023[15] - Total operating costs for the first three quarters of 2024 were ¥160,735,601.42, up from ¥153,771,750.31 in 2023, reflecting a year-on-year increase of 4.4%[16] - The company's operating revenue for the first three quarters of 2024 reached CNY 201,438,511.22, an increase of 15.5% compared to CNY 174,418,804.50 in the same period of 2023[25] Inventory and Accounts Receivable - Accounts receivable rose to CNY 22,364,464.32, up from CNY 13,693,052.04, marking an increase of around 63.5%[12] - Inventory increased to CNY 41,591,128.89 from CNY 29,203,685.03, reflecting a growth of approximately 42.5%[12] - The company’s inventory increased to CNY 35,789,932.72 from CNY 23,952,975.39 in the previous year, indicating a growth of 49.5%[22] Financial Activities - The total cash inflow from investment activities was CNY 565,953,748.93, slightly up from CNY 559,782,656.72 in the previous year[20] - The net cash flow from investment activities was negative at CNY -202,329,249.36, compared to a positive CNY 96,942,057.64 in the same period last year[20] - The company received CNY 562,796,926.00 from investment recoveries in Q3 2024, compared to CNY 555,200,000.00 in Q3 2023[29] - The company's cash outflow from financing activities was CNY 75,754,763.61, compared to CNY 20,463,922.12 in the previous year[21]